Company: SMNR
Filing Date: 2025-04-09
Form Type: 8-K
Source: 0001213900-25-030048
Chunk: 0

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-04-09
Form: 8-K
Item: Item 3.01
Chunk 0
---
Item 3.01. Notice of Delisting
or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As
previously disclosed in the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission (the " SEC")
on October 7, 2024, on October 2, 2024, Denali Capital Acquisition Corp. (the “ Company”) received a written notice
(the “ Notice”) from the Listing Qualifications Department (the “ Staff”) of The Nasdaq Stock Market LLC
(“ Nasdaq”) notifying the Company that the Company is not in compliance with Nasdaq Listing Rule 5450(b)(2)(A) (the
“ MVLS Rule”), which requires the Company to maintain a minimum Market Value of Listed Securities (“MVLS”)
of $50.0 million, and Nasdaq Listing Rule 5450(b)(3)(A) (the “ Total Assets Rule” and, together with the MVLS Rule,
the“ Listing Rules”), which requires the Company to maintain total assets and total revenue of at least $50.0 million
each for the most recently completed fiscal year or two of the three most recently completed fiscal years, for continued listing on the
Nasdaq Global Market.